Trial Profile
Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 09 May 2017 New trial record